Tingting Ma,1 Hongtian Wang,2 Xueyan Wang1
1Department of Allergy, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Laboratory of Bio-Characteristic Profiling for Evaluation of Rational Drug Use, Beijing 100038, People’s Republic of China; 2Department of Otolaryngology Head and Neck Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, People’s Republic of China
Correspondence: Hongtian Wang
Department of Otolaryngology Head and Neck Surgery, Beijing Shijitan Hospital, Capital Medical University, No. 10, Tieyi Road, Haidian District, Beijing 100038, People’s Republic of China
Tel +86 13391836668
Email [email protected]
Xueyan Wang
Department of Allergy, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Laboratory of Bio-characteristic Profiling for Evaluation of Rational Drug Use, No. 10, Tieyi Road, Haidian District, Beijing 100038, People’s Republic of China
Tel +86 13911612465
Email [email protected]
Background: Omalizumab has been proven effective and safety in treating seasonal allergic rhinitis (SAR) by several randomized clinical trials in many countries. However, there is lack of clinical reports of Chinese patients with SAR treated by omalizumab.
Objective: In the present real-world-designed study, we aimed to investigate the effectiveness of omalizumab in treating patients with SAR.
Methods: SAR patients administered omalizumab in various dosages were recruited, and follow-up was done. Their quality of life (QOL) and symptoms were assessed by the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), Total Nasal Symptoms Score (TNSS), Asthma Control Test (ACT), and clinical outcomes were compared between post- and pre-treatment conditions.
Results: Sixty SAR patients received omalizumab therapy in the study (mean age 35.47± 17.02 years, 35 females). Omalizumab treatment significantly improved the quality of life (change in RQLQ overall score: − 2.08± 1.01, paired t-test p< 0.001) and nasal symptoms (change in TNSS: − 7.33± 2.50, paired t-test p< 0.001) of SAR patients. In 21 patients with co-existing asthma, the ACT score significantly increased from 16.10 to 22.57 on average (paired t-test p< 0.001), indicating better-controlled asthma. Using a threshold of ≥ 1 point improvement in RQLQ overall score, 83.3% of patients responded to omalizumab. The responder group had a higher baseline RQLQ score and TNSS (p< 0.05), but both responders and non-responders had comparable scores after treatment. Multiple linear regression analysis identified the baseline RQLQ overall score as a predictor of change in the RQLQ score in omalizumab-treated SAR.
Conclusion: Omalizumab is effective and safe in SAR treatment in a real-world setting.
Keywords: omalizumab, seasonal allergic rhinitis, nasal symptoms score, quality of life, real world
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
